Text Size

Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

This study has been completed.
Sponsor:
Collaborator:
Sanofi
Information provided by:
Dattoli Cancer Center and Brachytherapy Research Institute
ClinicalTrials.gov Identifier:
NCT00264017
First received: December 6, 2005
Last updated: NA
Last verified: November 2005
History: No changes posted

December 6, 2005
December 6, 2005
November 2005
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis
Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.
Not Provided
Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Retrospective
Not Provided
Not Provided
Not Provided
Not Provided
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
November 2005
Not Provided

Inclusion Criteria:

  • Males age 45-80 years
  • Diagnosis of prostate cancer
  • Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation
  • Baseline AUA score< or =12
  • May be on antiandrogenand/or alpha reductase therapy
  • Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -

Exclusion Criteria:

  • History of insulin-dependent diabetes
  • Uncontrolled hypertention
  • History of symptomtic hypotension (including syncope and dizziness)
  • Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention
  • Pre-existing prostatitis either continuous or intermittent
  • Concurrent use of any other anticholinergics
  • previous or concurrent usage of LHRH agonist
Male
45 Years to 80 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00264017
L0087
Not Provided
Not Provided
Dattoli Cancer Center and Brachytherapy Research Institute
Sanofi
Principal Investigator: Michael J Dattoli, MD Dattoli Cancer Center and Brachytherapy Research Institute
Dattoli Cancer Center and Brachytherapy Research Institute
November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP